The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
FDA approves dara-VTd for transplant eligible, newly diagnosed multiple myeloma
The United States (US) Food & Drug Administration (FDA) have approved the use of daratumumab (dara), in combination with bortezomib (V), thalidomide (T) and dexamethasone (dara-VTd) for the treatment of transplant eligible patients with newly diagnosed multiple myeloma (NDMM). The approval is based on part one of the CASSIOPEIA trial results which were presented earlier this year at the American Society of Clinical Oncology (ASCO) meeting by Professor Philippe Moreau, and were simultaneously published in The Lancet.1
CASSIOPEIA, part one2
Data given as dara-VTd versus VTd
In the phase III CASSIOPEIA trial, patients received either dara-VTd (n= 543) or VTd (n= 542) as induction therapy, followed by autologous stem cell transplant (ASCT) and consolidation with dara-VTd or VTd alone.
In part one of the trial, the primary endpoint was post-consolidation stringent complete response (sCR).3 sCR was improved in the dara-VTd arm (29% vs 20%, odds ratio: 1.6, p= 0.001). Additionally, dara-VTd provided higher rates of measurable residual disease (MRD)-negativity at the rate of 10-5 (64% vs 44%, p< 0.0001). Eighteen-month progression-free survival (PFS) was also improved with dara-VTd (93% vs 85%, hazard ratio: 0.47, p< 0.0001) and median overall survival (OS) was not reached in either arm.
To read these results in more detail, click here.
CASSIOPEIA, part two1,3
Patients who achieve a response to induction and consolidation will subsequently be re-randomized to maintenance therapy with daratumumab (16mg/kg every eight weeks for up to two years) or observation. The primary endpoint of part two is post-maintenance PFS.1,2
References